Fundz
New|Fundz now works inside Claude2 min

AI made execution free. Knowing first is the whole game now.

The advantage goes to whoever is first into the right conversations, most often. Fundz stacks those odds: more of the moments that create demand than anyone else catches, as they happen, matched to who you sell to, with the decision maker to call. Now it answers in Claude too: ask for today’s leads and who to reach, then write the note in the same window. Not a feed. Not a list you rent. A system for being first.

Trusted by

OracleSnowflakeCloudflareLinkedInGoogleSalesforce
4.8/5 on G2· Since 2015

Engitix Appoints Sonia Quaratino as Executive Vice President Chief Medical Officer

PRIVATESep 23, 2026about 2 hours ago

Position

Executive Vice President

Company

Engitix Ltd

Sonia Quaratino
London

Description

Engitix Ltd. has announced the appointment of Sonia Quaratino, MD, PhD, as the Executive Vice President Chief Medical Officer. Dr

Company Information

Company

Engitix Ltd

Location

London, Ontario, Canada

About

Engitix is developing a portfolio of internal & partnered drug discovery programmes in fibrosis and solid tumours using its pioneering human extracellular matrix (ECM) platform. The use of more physiologically relevant human in vitro models is transforming the ability to identify new targets, to develop more advanced treatments and to enable a more accurate prediction of the efficacy of therapeutic candidates. It has partnerships with Dompé farmaceutici and Takeda, and a previous partnership with Morphic Therapeutics. Engitix was founded in 2016 to commercialise cutting-edge research at the Institute for Liver and Digestive Health, Division of Medicine, University College London (UCL). The company is headquartered in Westworks, White City Place, London, UK. A private company, Engitix investors include Netherton Investments, a fund investing on behalf of Mike Platt, and Dompé farmaceutici, an Italian and US-based biopharmaceutical company. For more information, please visit www.engitix.com Follow us on LinkedIn

Fundz sees it the moment Engitix Ltd changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Sam
Senior decision-maker at this company
••••••••@••••••••

See Sam's verified email →

Giuseppe
Senior decision-maker at this company
••••••••@••••••••

See Giuseppe's verified email →

Predictive Intelligence
Strategic

ML-powered predictions for Engitix Ltd's next move

Learn about Strategic plan

Executive Insights

Based on hiring data
New executive impact window
87% of new executives make significant technology decisions within first 100 days
Budget influence
C-level executives control 73% of technology spending decisions
Transformation catalyst
65% of new senior hires launch digital transformation initiatives
Vendor review timeline
New executives typically review existing vendors within 6 months

Engitix Ltd changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 285,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.